BrightPath Biotherapeutics Co., Ltd.
TSE:4594.T
87 (JPY) • At close August 29, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) JPY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1.133 | 0.072 | 5.28 | 15.408 | 2.504 | 11.3 | 155.808 | 354.41 | 529.612 | 822.556 | 821.625 |
| Cost of Revenue
| 0.032 | 0.413 | 1.895 | 3.317 | 1.145 | 4.467 | 70.702 | 315.174 | 524.913 | 771.657 | 766.619 |
| Gross Profit
| 1.101 | -0.341 | 3.385 | 12.091 | 1.359 | 6.833 | 85.106 | 39.236 | 4.699 | 50.899 | 55.006 |
| Gross Profit Ratio
| 0.972 | -4.736 | 0.641 | 0.785 | 0.543 | 0.605 | 0.546 | 0.111 | 0.009 | 0.062 | 0.067 |
| Reseach & Development Expenses
| 888.064 | 0 | 1,168.473 | 1,135.847 | 1,408.443 | 1,484.854 | 1,387.674 | 1,146.584 | 816.783 | 848.993 | 0 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 74 | 67 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 419.804 | 231.195 | 0 | 0 |
| SG&A
| 1,162.019 | 1,154.738 | 285.251 | 317.154 | 259.03 | 286.857 | 308.825 | 493.804 | 298.195 | 190.563 | 0 |
| Other Expenses
| -888.064 | 0 | 16.719 | 35.123 | 66.688 | 62.471 | -10.265 | -0.081 | 12.562 | 0 | 86.092 |
| Operating Expenses
| 1,162.019 | 1,154.738 | 1,470.443 | 1,488.124 | 1,734.161 | 1,834.182 | 1,750.655 | 1,600.968 | 1,118.249 | 1,039.649 | 547.192 |
| Operating Income
| -1,160.918 | -1,155.079 | -1,467.059 | -1,476.033 | -1,732.802 | -1,827.349 | -1,665.548 | -1,561.732 | -1,113.55 | -988.75 | -492.186 |
| Operating Income Ratio
| -1,024.641 | -16,042.764 | -277.852 | -95.797 | -692.014 | -161.712 | -10.69 | -4.407 | -2.103 | -1.202 | -0.599 |
| Total Other Income Expenses Net
| 11.669 | -11.103 | -16.674 | -5.739 | 15.588 | -32.512 | -214.981 | -10.198 | -3.378 | -4.227 | 83.754 |
| Income Before Tax
| -1,149.249 | -1,166.182 | -1,483.733 | -1,481.772 | -1,717.214 | -1,859.861 | -1,880.529 | -1,573.292 | -1,116.928 | -992.977 | -408.432 |
| Income Before Tax Ratio
| -1,014.342 | -16,196.972 | -281.01 | -96.169 | -685.788 | -164.589 | -12.07 | -4.439 | -2.109 | -1.207 | -0.497 |
| Income Tax Expense
| 1.9 | 1.9 | 1.9 | 2.42 | 2.42 | -2.087 | 3.788 | 5.124 | 5.071 | 1.487 | 4.003 |
| Net Income
| -1,151.149 | -1,168.082 | -1,485.633 | -1,484.192 | -1,719.634 | -1,857.774 | -1,884.318 | -1,577.142 | -1,113.661 | -994.464 | -412.435 |
| Net Income Ratio
| -1,016.019 | -16,223.361 | -281.37 | -96.326 | -686.755 | -164.405 | -12.094 | -4.45 | -2.103 | -1.209 | -0.502 |
| EPS
| -14.12 | -18.21 | -24.9 | -28.55 | -36.14 | -44.2 | -44.95 | -41.25 | -32.74 | -35.28 | -20.34 |
| EPS Diluted
| -14.12 | -18.21 | -24.9 | -28.55 | -36.14 | -44.2 | -44.95 | -41.25 | -32.74 | -35.28 | -20.34 |
| EBITDA
| -1,149.249 | -1,165.786 | -1,466.952 | -1,446.287 | -1,650.527 | -1,764.879 | -1,582.779 | -1,488.523 | -1,070.843 | -973.673 | -399.63 |
| EBITDA Ratio
| -1,014.342 | -16,191.472 | -277.832 | -93.866 | -659.156 | -156.184 | -10.159 | -4.2 | -2.022 | -1.184 | -0.486 |